Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: A randomized trial in healthy men

被引:55
作者
Gouni-Berthold, Ioanna [1 ]
Berthold, Heiner K. [2 ]
Gylling, Helena [3 ,4 ]
Hallikainen, Maarit [3 ,4 ]
Giannakidou, Eleni
Stier, Sebastian [5 ]
Ko, Yon [5 ]
Patel, Dilip [6 ]
Soutar, Anne K. [6 ]
Seedorf, Udo [7 ]
Mantzoros, Christos S. [8 ]
Plat, Jogchum [9 ]
Krone, Wilhelm [1 ]
机构
[1] Univ Cologne, Dept Internal Med 2, D-50937 Cologne, Germany
[2] Univ Bonn, Fac Med, Clin Pharmacol, D-5300 Bonn, Germany
[3] Univ Kuopio, Dept Clin Nutr, FIN-70211 Kuopio, Finland
[4] Kuopio Univ Hosp, SF-70210 Kuopio, Finland
[5] Univ Bonn, Med Policlin, D-5300 Bonn, Germany
[6] Hammersmith Hosp, MRC Clin Sci Ctr, London, England
[7] Univ Munster, Leibniz Inst Arteriosclerosis Res, Munster, Germany
[8] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Endocrinol Diabet & Metab, Boston, MA 02115 USA
[9] Univ Maastricht, Dept Human Biol, Maastricht, Netherlands
基金
英国医学研究理事会;
关键词
ezetimibe; simvastatin; LDL receptor; HMG-CoA reductase; gene expression; PCSK9; NPC1L1;
D O I
10.1016/j.atherosclerosis.2007.09.034
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The combination of simvastatin, an HMG-CoA reductase inhibitor, and ezetimibe, an inhibitor of Niemann-Pick C1-like 1 protein, decreases cholesterol synthesis and absorption and reduces circulating LDL-cholesterol concentrations. The molecular mechanisms underlying the pronounced lipid-lowering effects of this combination have not been fully elucidated in humans. Methods and results: One center, prospective, randomized, parallel three-group study in 72 healthy men (mean age 32 19 years, mean body mass index 25.7 +/- 3.2 kg/m(2)). Each group of twenty-four subjects received a 14-day treatment with either ezetimibe (10mg/day), simvastatin (40 mg/day) or their combination. Lipid levels, the ratio of non-cholesterol sterols to cholesterol concentrations (used as markers of cholesterol synthesis and absorption), cell surface LDL receptor (LDLR) protein as well as LDLR and HMG-CoA reductase gene expression in mononuclear blood cells were measured at baseline and at the end of the study. LDL-C decreased in all groups. Simvastatin decreased, ezetimibe increased and their combination had no effect on HMG-CoA reductase activity. Simvastatin and the combination of ezetimibe and simvastatin increased the HMG-CoA reductase and LDLR gene expression while ezetimibe had no effect. The cell surface LDLR protein expression remained unchanged in all groups. The combination of ezetimibe and simvastatin increased the expression of the serine protease proprotein convertase subtilisin/kexin 9 (PCSK9), an enzyme shown to down-regulate LDLR protein levels. Conclusions: The co-administration of ezetimibe and simvastatin abrogates the ezetin-tibe-induced increase in cholesterol synthesis and up-regulates the LDLR gene but not protein expression, an effect possibly mediated through a parallel upregulation of PCSK9 expression. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:198 / 207
页数:10
相关论文
共 40 条
[31]   LOW-DENSITY-LIPOPROTEIN RECEPTOR AND 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE GENE-EXPRESSION IN HUMAN MONONUCLEAR LEUKOCYTES IS REGULATED COORDINATELY AND PARALLELS GENE-EXPRESSION IN HUMAN LIVER [J].
POWELL, EE ;
KROON, PA .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (05) :2168-2174
[32]   Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption [J].
Repa, JJ ;
Turley, SD ;
Quan, G ;
Dietschy, JM .
JOURNAL OF LIPID RESEARCH, 2005, 46 (04) :779-789
[33]   Regulation of hepatic low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and cholesterol 7α-hydroxylase mRNAs in human liver [J].
Rudling, M ;
Angelin, B ;
Ståhle, L ;
Reihnér, E ;
Sahlin, S ;
Olivecrona, H ;
Björkhem, I ;
Einarsson, C .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (09) :4307-4313
[34]   Cholesterol absorption inhibitor Ezetimibe blocks uptake of oxidized LDL in human macrophages [J].
Seedorf, U ;
Engel, T ;
Lueken, A ;
Bode, G ;
Lorkowski, S ;
Assmann, G .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 320 (04) :1337-1341
[35]   Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia [J].
Sudhop, T ;
von Bergmann, K .
DRUGS, 2002, 62 (16) :2333-2347
[36]   Inhibition of intestinal cholesterol absorption by ezetimibe in humans [J].
Sudhop, T ;
Lütjohann, D ;
Kodal, A ;
Igel, M ;
Tribble, DL ;
Shah, S ;
Perevozskaya, I ;
von Bergmann, K .
CIRCULATION, 2002, 106 (15) :1943-1948
[37]   The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin [J].
Telford, Dawn E. ;
Sutherland, Brian G. ;
Edwards, Jane Y. ;
Andrews, Joseph D. ;
Barrett, P. Hugh R. ;
Huff, Murray W. .
JOURNAL OF LIPID RESEARCH, 2007, 48 (03) :699-708
[38]   Competitive reverse transcription polymerase chain reaction for the quantification of p53 and mdm2 mRNA expression [J].
Totzke, G ;
Sachinidis, A ;
Vetter, H ;
Ko, Y .
MOLECULAR AND CELLULAR PROBES, 1996, 10 (06) :427-433
[39]   Effect of Ezetimibe on the in vivo kinetics of ApoB-48 and ApoB-100 in men with primary hypercholesterolemia [J].
Tremblay, AJ ;
Lamarche, B ;
Cohn, JS ;
Hogue, JC ;
Couture, P .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (05) :1101-1106
[40]   Caveolin-1 is not required for murine intestinal cholesterol transport [J].
Valasek, MA ;
Weng, J ;
Shaul, PW ;
Anderson, RGW ;
Repa, JJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (30) :28103-28109